GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors

Roberto Latagliata, Massimo Breccia, Paola Fazi, Marco Vignetti, Francesco di Raimondo, Marco Sborgia, Donatella Vincelli, Anna Candoni, Flavia Salvi, Serena Rupoli, Giovanni Martinelli, Maria Grazia Kropp, Anna Tonso, Adriano Venditti, Lorella Melillo, Giuseppe Cimino, Maria Concetta Petti, Giuseppe Avvisati, Francesco Lo-Coco, Franco Mandelli

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

To reduce toxicity in elderly patients with acute promyelocytic leukaemia, in 1997 the Gruppo Italiano Malattie Ematologiche Dell'Adulto (GIMEMA) started an amended protocol for patients aged >60years, with the same induction [all-trans retinoic acid (ATRA)+idarubicin] as in younger patients, followed by a single consolidation course (idarubicin+cytarabine) and maintenance with intermittent ATRA. Among 60 enrolled patients, 54 (90%) achieved haematological remission and six died during induction. Four additional patients died in complete remission (CR) from haemorrhage (2) and infection (2) prior or during consolidation therapy. Eleven patients relapsed at a median time of 17.5months from CR. The 5-year overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) rates were 76.1%, 64.6% and 27.4%, respectively. Univariate analysis identified a performance score (PS)=2 as the only significant adverse prognostic factor for both OS (P=0.017) and DFS (P=0.0003). Male sex had an unfavourable impact on DFS (P=0.021) and on CIR (P=0.019), but not on OS (P=0.234). In multivariate analysis for DFS, only PS=2 retained prognostic significance (HR=4.5, P=0.0083). In conclusion, the amended GIMEMA protocol is effective, with similar relapse rate and inferior toxicity compared to the original AIDA 0493. However, considering the recent availability of effective new agents, a less aggressive approach should be tested in this setting.

Original languageEnglish
Pages (from-to)564-568
Number of pages5
JournalBritish Journal of Haematology
Volume154
Issue number5
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Acute Promyelocytic Leukemia
Disease-Free Survival
Idarubicin
Tretinoin
Recurrence
Survival
Cytarabine
Incidence
Multivariate Analysis
Maintenance
Hemorrhage
Infection

Keywords

  • Acute promyelocytic leukaemia
  • All-trans retinoic acid
  • Consolidation therapy
  • Elderly acute promyelocytic leukaemia

ASJC Scopus subject areas

  • Hematology

Cite this

GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. / Latagliata, Roberto; Breccia, Massimo; Fazi, Paola; Vignetti, Marco; di Raimondo, Francesco; Sborgia, Marco; Vincelli, Donatella; Candoni, Anna; Salvi, Flavia; Rupoli, Serena; Martinelli, Giovanni; Kropp, Maria Grazia; Tonso, Anna; Venditti, Adriano; Melillo, Lorella; Cimino, Giuseppe; Petti, Maria Concetta; Avvisati, Giuseppe; Lo-Coco, Francesco; Mandelli, Franco.

In: British Journal of Haematology, Vol. 154, No. 5, 09.2011, p. 564-568.

Research output: Contribution to journalArticle

Latagliata, R, Breccia, M, Fazi, P, Vignetti, M, di Raimondo, F, Sborgia, M, Vincelli, D, Candoni, A, Salvi, F, Rupoli, S, Martinelli, G, Kropp, MG, Tonso, A, Venditti, A, Melillo, L, Cimino, G, Petti, MC, Avvisati, G, Lo-Coco, F & Mandelli, F 2011, 'GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors', British Journal of Haematology, vol. 154, no. 5, pp. 564-568. https://doi.org/10.1111/j.1365-2141.2011.08593.x
Latagliata, Roberto ; Breccia, Massimo ; Fazi, Paola ; Vignetti, Marco ; di Raimondo, Francesco ; Sborgia, Marco ; Vincelli, Donatella ; Candoni, Anna ; Salvi, Flavia ; Rupoli, Serena ; Martinelli, Giovanni ; Kropp, Maria Grazia ; Tonso, Anna ; Venditti, Adriano ; Melillo, Lorella ; Cimino, Giuseppe ; Petti, Maria Concetta ; Avvisati, Giuseppe ; Lo-Coco, Francesco ; Mandelli, Franco. / GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. In: British Journal of Haematology. 2011 ; Vol. 154, No. 5. pp. 564-568.
@article{5ce7c4811a694c009b0982304a3fb96a,
title = "GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors",
abstract = "To reduce toxicity in elderly patients with acute promyelocytic leukaemia, in 1997 the Gruppo Italiano Malattie Ematologiche Dell'Adulto (GIMEMA) started an amended protocol for patients aged >60years, with the same induction [all-trans retinoic acid (ATRA)+idarubicin] as in younger patients, followed by a single consolidation course (idarubicin+cytarabine) and maintenance with intermittent ATRA. Among 60 enrolled patients, 54 (90{\%}) achieved haematological remission and six died during induction. Four additional patients died in complete remission (CR) from haemorrhage (2) and infection (2) prior or during consolidation therapy. Eleven patients relapsed at a median time of 17.5months from CR. The 5-year overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) rates were 76.1{\%}, 64.6{\%} and 27.4{\%}, respectively. Univariate analysis identified a performance score (PS)=2 as the only significant adverse prognostic factor for both OS (P=0.017) and DFS (P=0.0003). Male sex had an unfavourable impact on DFS (P=0.021) and on CIR (P=0.019), but not on OS (P=0.234). In multivariate analysis for DFS, only PS=2 retained prognostic significance (HR=4.5, P=0.0083). In conclusion, the amended GIMEMA protocol is effective, with similar relapse rate and inferior toxicity compared to the original AIDA 0493. However, considering the recent availability of effective new agents, a less aggressive approach should be tested in this setting.",
keywords = "Acute promyelocytic leukaemia, All-trans retinoic acid, Consolidation therapy, Elderly acute promyelocytic leukaemia",
author = "Roberto Latagliata and Massimo Breccia and Paola Fazi and Marco Vignetti and {di Raimondo}, Francesco and Marco Sborgia and Donatella Vincelli and Anna Candoni and Flavia Salvi and Serena Rupoli and Giovanni Martinelli and Kropp, {Maria Grazia} and Anna Tonso and Adriano Venditti and Lorella Melillo and Giuseppe Cimino and Petti, {Maria Concetta} and Giuseppe Avvisati and Francesco Lo-Coco and Franco Mandelli",
year = "2011",
month = "9",
doi = "10.1111/j.1365-2141.2011.08593.x",
language = "English",
volume = "154",
pages = "564--568",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors

AU - Latagliata, Roberto

AU - Breccia, Massimo

AU - Fazi, Paola

AU - Vignetti, Marco

AU - di Raimondo, Francesco

AU - Sborgia, Marco

AU - Vincelli, Donatella

AU - Candoni, Anna

AU - Salvi, Flavia

AU - Rupoli, Serena

AU - Martinelli, Giovanni

AU - Kropp, Maria Grazia

AU - Tonso, Anna

AU - Venditti, Adriano

AU - Melillo, Lorella

AU - Cimino, Giuseppe

AU - Petti, Maria Concetta

AU - Avvisati, Giuseppe

AU - Lo-Coco, Francesco

AU - Mandelli, Franco

PY - 2011/9

Y1 - 2011/9

N2 - To reduce toxicity in elderly patients with acute promyelocytic leukaemia, in 1997 the Gruppo Italiano Malattie Ematologiche Dell'Adulto (GIMEMA) started an amended protocol for patients aged >60years, with the same induction [all-trans retinoic acid (ATRA)+idarubicin] as in younger patients, followed by a single consolidation course (idarubicin+cytarabine) and maintenance with intermittent ATRA. Among 60 enrolled patients, 54 (90%) achieved haematological remission and six died during induction. Four additional patients died in complete remission (CR) from haemorrhage (2) and infection (2) prior or during consolidation therapy. Eleven patients relapsed at a median time of 17.5months from CR. The 5-year overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) rates were 76.1%, 64.6% and 27.4%, respectively. Univariate analysis identified a performance score (PS)=2 as the only significant adverse prognostic factor for both OS (P=0.017) and DFS (P=0.0003). Male sex had an unfavourable impact on DFS (P=0.021) and on CIR (P=0.019), but not on OS (P=0.234). In multivariate analysis for DFS, only PS=2 retained prognostic significance (HR=4.5, P=0.0083). In conclusion, the amended GIMEMA protocol is effective, with similar relapse rate and inferior toxicity compared to the original AIDA 0493. However, considering the recent availability of effective new agents, a less aggressive approach should be tested in this setting.

AB - To reduce toxicity in elderly patients with acute promyelocytic leukaemia, in 1997 the Gruppo Italiano Malattie Ematologiche Dell'Adulto (GIMEMA) started an amended protocol for patients aged >60years, with the same induction [all-trans retinoic acid (ATRA)+idarubicin] as in younger patients, followed by a single consolidation course (idarubicin+cytarabine) and maintenance with intermittent ATRA. Among 60 enrolled patients, 54 (90%) achieved haematological remission and six died during induction. Four additional patients died in complete remission (CR) from haemorrhage (2) and infection (2) prior or during consolidation therapy. Eleven patients relapsed at a median time of 17.5months from CR. The 5-year overall survival (OS), disease-free survival (DFS) and cumulative incidence of relapse (CIR) rates were 76.1%, 64.6% and 27.4%, respectively. Univariate analysis identified a performance score (PS)=2 as the only significant adverse prognostic factor for both OS (P=0.017) and DFS (P=0.0003). Male sex had an unfavourable impact on DFS (P=0.021) and on CIR (P=0.019), but not on OS (P=0.234). In multivariate analysis for DFS, only PS=2 retained prognostic significance (HR=4.5, P=0.0083). In conclusion, the amended GIMEMA protocol is effective, with similar relapse rate and inferior toxicity compared to the original AIDA 0493. However, considering the recent availability of effective new agents, a less aggressive approach should be tested in this setting.

KW - Acute promyelocytic leukaemia

KW - All-trans retinoic acid

KW - Consolidation therapy

KW - Elderly acute promyelocytic leukaemia

UR - http://www.scopus.com/inward/record.url?scp=80051593309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051593309&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08593.x

DO - 10.1111/j.1365-2141.2011.08593.x

M3 - Article

VL - 154

SP - 564

EP - 568

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -